logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO-SITC 2019—Neoadjuvant atezolizumab yields encouraging MPR rate in NSCLC

Preliminary analysis of an ongoing multicenter phase 2 trial.